13.04
price down icon4.61%   -0.63
pre-market  Pre-mercato:  13.07   0.03   +0.23%
loading
Precedente Chiudi:
$13.67
Aprire:
$13.55
Volume 24 ore:
3.03M
Relative Volume:
1.30
Capitalizzazione di mercato:
$1.55B
Reddito:
$59.61M
Utile/perdita netta:
$-262.14M
Rapporto P/E:
-3.3265
EPS:
-3.92
Flusso di cassa netto:
$-247.49M
1 W Prestazione:
-6.72%
1M Prestazione:
-11.59%
6M Prestazione:
+0.00%
1 anno Prestazione:
+50.58%
Intervallo 1D:
Value
$12.83
$13.55
Intervallo di 1 settimana:
Value
$12.83
$14.30
Portata 52W:
Value
$6.99
$17.75

Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile

Name
Nome
Arcutis Biotherapeutics Inc
Name
Telefono
805-418-5006
Name
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Name
Dipendente
342
Name
Cinguettio
@ArcutisBio
Name
Prossima data di guadagno
2024-12-06
Name
Ultimi documenti SEC
Name
ARQT's Discussions on Twitter

Confronta ARQT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ARQT
Arcutis Biotherapeutics Inc
13.04 1.67B 59.61M -262.14M -247.49M -3.92
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-12-30 Iniziato H.C. Wainwright Buy
2024-08-28 Iniziato Jefferies Buy
2024-01-03 Aggiornamento Mizuho Neutral → Buy
2023-10-26 Downgrade Mizuho Buy → Neutral
2023-10-13 Downgrade Goldman Buy → Neutral
2022-09-07 Iniziato Needham Buy
2022-03-17 Iniziato Goldman Buy
2021-06-30 Iniziato Mizuho Buy
2021-05-27 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2020-11-09 Aggiornamento Goldman Neutral → Buy
2020-10-08 Iniziato Truist Buy
2020-02-25 Iniziato Cantor Fitzgerald Overweight
2020-02-25 Iniziato Cowen Outperform
2020-02-25 Iniziato Goldman Neutral
2020-02-25 Iniziato Guggenheim Buy
Mostra tutto

Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie

pulisher
May 31, 2025

Possible Bearish Signals With Arcutis Biotherapeutics Insiders Disposing Stock - simplywall.st

May 31, 2025
pulisher
May 30, 2025

Arcutis Biotherapeutics SVP sells $24,806 in stock By Investing.com - Investing.com South Africa

May 30, 2025
pulisher
May 30, 2025

Arcutis Biotherapeutics SVP sells $24,806 in stock - Investing.com Australia

May 30, 2025
pulisher
May 29, 2025

Arcutis to Present at the Goldman Sachs 46th Annual Global Healthcare Conference - The Manila Times

May 29, 2025
pulisher
May 29, 2025

Immuno-Dermatology Leader Arcutis Set for Key Goldman Sachs Healthcare Conference Presentation - Stock Titan

May 29, 2025
pulisher
May 26, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Bank of America Corp DE - Defense World

May 26, 2025
pulisher
May 25, 2025

Needham & Company LLC Reaffirms Buy Rating for Arcutis Biotherapeutics (NASDAQ:ARQT) - Defense World

May 25, 2025
pulisher
May 24, 2025

Arcutis wins FDA nod for Zoryve foam for plaque psoriasis - MSN

May 24, 2025
pulisher
May 23, 2025

Analyst Expectations For Arcutis Biotherapeutics's Future - Benzinga

May 23, 2025
pulisher
May 23, 2025

ARQT Analyst Reiterates Buy Rating with $20 Price Target | ARQT Stock News - GuruFocus

May 23, 2025
pulisher
May 23, 2025

Arcutis’ ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - BioSpace

May 23, 2025
pulisher
May 22, 2025

FDA approves roflumilast foam 0.3% for scalp, body psoriasis - Contemporary Pediatrics

May 22, 2025
pulisher
May 22, 2025

FDA approves ZORYVE foam for plaque psoriasis treatment - Investing.com Australia

May 22, 2025
pulisher
May 22, 2025

FDA Approves Arcutis' (ARQT) Zoryve Foam for Psoriasis Treatment - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Arcutis Biotherapeutics' Foam Psoriasis Treatment Gets FDA Approval - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

FDA Approval Boosts Arcutis Biotherapeutics (ARQT) with New Psor - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Arcutis wins FDA nod for Zoryve foam in psoriasis (ARQT:NASDAQ) - Seeking Alpha

May 22, 2025
pulisher
May 22, 2025

Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older | ARQT Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

FDA approves ZORYVE foam for plaque psoriasis treatment By Investing.com - Investing.com India

May 22, 2025
pulisher
May 22, 2025

Understanding Roflumilast Foam's FDA Approval for Scalp and Body Psoriasis, with Jennifer Soung, MD - HCPLive

May 22, 2025
pulisher
May 22, 2025

Arcutis' ZORYVE® (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older - The Manila Times

May 22, 2025
pulisher
May 22, 2025

Better Weight Loss Stock: Amgen or Viking Therapeutics? - The Globe and Mail

May 22, 2025
pulisher
May 21, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World

May 21, 2025
pulisher
May 21, 2025

79,815 Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Acquired by BNP Paribas Financial Markets - Defense World

May 21, 2025
pulisher
May 16, 2025

The Manufacturers Life Insurance Company Sells 1,547 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World

May 16, 2025
pulisher
May 16, 2025

When the Price of (ARQT) Talks, People Listen - news.stocktradersdaily.com

May 16, 2025
pulisher
May 16, 2025

ARQT: Key Insights from Genital Psoriasis Consensus Statements | - GuruFocus

May 16, 2025
pulisher
May 16, 2025

New Consensus Statements on Impact of Genital Psoriasis on Patie - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Northern Trust Corp Acquires 54,541 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World

May 16, 2025
pulisher
May 15, 2025

New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice - The Manila Times

May 15, 2025
pulisher
May 15, 2025

Arcutis Biotherapeutics Publishes Expert Consensus on Genital Psoriasis to Enhance Patient Care and Treatment Decision-Making - Nasdaq

May 15, 2025
pulisher
May 15, 2025

Medical Breakthrough: Experts Release 14 Game-Changing Guidelines for Genital Psoriasis Treatment - Stock Titan

May 15, 2025
pulisher
May 14, 2025

Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy - openPR.com

May 14, 2025
pulisher
May 14, 2025

Chronic Hand Eczema Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics - Barchart.com

May 14, 2025
pulisher
May 14, 2025

Director’s Bold Move: A Major Investment in Arcutis Biotherapeutics - TipRanks

May 14, 2025
pulisher
May 13, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Sold by Price T Rowe Associates Inc. MD - Defense World

May 13, 2025
pulisher
May 11, 2025

Hsbc Holdings PLC Increases Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Defense World

May 11, 2025
pulisher
May 10, 2025

Analysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and AMN Healthcare Services (AMN) - The Globe and Mail

May 10, 2025
pulisher
May 09, 2025

Arcutis outlines growth potential with ZORYVE expansions and market penetration - MSN

May 09, 2025
pulisher
May 09, 2025

Earnings Update: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts - simplywall.st

May 09, 2025
pulisher
May 09, 2025

What is HC Wainwright’s Forecast for ARQT Q1 Earnings? - Defense World

May 09, 2025
pulisher
May 09, 2025

Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates - MSN

May 09, 2025
pulisher
May 08, 2025

Arcutis Biotherapeutics: Zoryve foam treatment resulted in major improvements - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Arcutis Biotherapeutics First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q1 2025 Earnings Call Transcript - Insider Monkey

May 08, 2025
pulisher
May 07, 2025

Arcutis Biotherapeutics Reports Strong Q1 Earnings Growth - TipRanks

May 07, 2025
pulisher
May 07, 2025

Jefferies lifts Arcutis stock target to $20 on strong sales By Investing.com - Investing.com South Africa

May 07, 2025
pulisher
May 07, 2025

ZORYVE foam shows promise in psoriasis treatment By Investing.com - Investing.com South Africa

May 07, 2025
pulisher
May 07, 2025

ZORYVE foam shows promise in psoriasis treatment - Investing.com

May 07, 2025
pulisher
May 07, 2025

Arcutis Announces Publication of Positive Data from ARRECTOR Tri - GuruFocus

May 07, 2025

Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):